List of Excipients in Branded Drug VECTICAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galderma Laboratories LP	VECTICAL	calcitriol	0299-2012	.ALPHA.-TOCOPHEROL, DL-
Galderma Laboratories LP	VECTICAL	calcitriol	0299-2012	MINERAL OIL
Galderma Laboratories LP	VECTICAL	calcitriol	0299-2012	PETROLATUM

Vectical Excipient Strategy and Commercial Opportunities for Calcitriol Ointment

Last updated: August 24, 2026

Vectical is a prescription calcitriol ointment containing 3 mcg/g of calcitriol for topical treatment of mild-to-moderate plaque psoriasis in adults. Its commercial value is tied less to active-ingredient novelty than to formulation performance: dose uniformity at microgram strength, anhydrous stability, skin feel, packaging, and patient adherence. The clearest opportunities are generic or branded-generic development, improved semi-solid delivery systems, lower-grease excipients, and differentiated packaging.

What is Vectical and how does its formulation work?

Vectical contains calcitriol, the active form of vitamin D3, at a concentration of 0.003% w/w. The product is an ointment intended for topical application to psoriatic plaques. Calcitriol reduces keratinocyte proliferation and modulates inflammatory signaling associated with psoriasis.

Attribute	Vectical
Active ingredient	Calcitriol
Strength	3 mcg/g, 0.003% w/w
Dosage form	Topical ointment
Indication	Mild-to-moderate plaque psoriasis
Initial FDA approval	2009
Application	Affected skin, excluding specified sensitive areas
Key safety concern	Hypercalcemia and hypercalciuria
Regulatory pathway	Prescription NDA
Original commercial sponsor	Galderma Laboratories
Reference NDA	021421

The FDA-approved label limits weekly exposure and cautions against use on the face, scalp, axillae, groin, mucous membranes, and other sensitive areas. Patients are also instructed to avoid excessive exposure to natural or artificial sunlight during treatment.[1]

Vectical’s excipient system is important because calcitriol is present at a very low concentration. Small changes in blending, particle distribution, solubilization, or filling can affect delivered dose and content uniformity.

What excipients are used in Vectical ointment?

Vectical’s inactive ingredients are mineral oil, white petrolatum, polysorbate 80, and alpha-tocopherol. The formulation is an oil-based ointment rather than a water-containing cream or lotion.[1,2]

Excipient	Likely formulation function
White petrolatum	Primary occlusive base, emolliency, viscosity, barrier formation
Mineral oil	Emollient, viscosity adjustment, spreadability
Polysorbate 80	Wetting and dispersion support for calcitriol
Alpha-tocopherol	Antioxidant protection for oxidation-sensitive components

The excipient architecture has four commercial advantages:

1. It avoids aqueous-phase microbial preservation requirements.
2. It supports prolonged skin contact.
3. It reduces the number of formulation variables compared with a multiphase cream.
4. It provides a platform for low-concentration dosing in an anhydrous base.

The main disadvantages are the conventional ointment profile: greasiness, limited cosmetic acceptability, transfer to clothing, and potentially poor adherence when large body areas require treatment.

How should an excipient strategy address calcitriol stability?

Calcitriol is sensitive to degradation pathways associated with light, oxygen, heat, and formulation microenvironment. An excipient strategy should therefore protect chemical stability while preserving dose uniformity.

Oxidation control

Alpha-tocopherol is a logical antioxidant for an oil-based system. Development work should evaluate:

• Alpha-tocopherol concentration and grade
• Peroxide value of mineral oil and petrolatum
• Oxygen exposure during compounding and filling
• Headspace oxygen in the final container
• Metal-catalyzed degradation
• Compatibility with tube or pump materials

The formulation should use low-peroxide excipients and controlled storage conditions. Antioxidant selection should be based on stability data rather than label familiarity. Excess antioxidant can affect color, odor, or compatibility with packaging components.

Light protection

Calcitriol is a vitamin D analog with potential photochemical sensitivity. A commercial product should evaluate opaque aluminum tubes, multilayer polymer tubes, airless systems, and secondary cartons. Clear containers would create unnecessary regulatory and stability risk unless supported by robust photostability data under ICH conditions.[3]

Water control

An anhydrous ointment can reduce hydrolytic degradation and microbial risk. Water activity should be controlled during manufacturing, even if the finished product does not require a conventional preservative system. Introducing water to create a cream may improve cosmetic properties but adds preservative, emulsion, and microbial-control requirements.

What formulation patents and intellectual-property rights protect Vectical?

Vectical’s principal defensibility is based on the approved drug product, formulation know-how, manufacturing controls, and regulatory data rather than a new molecular entity. Calcitriol itself is an established vitamin D analog, and broad composition-of-matter protection is not expected to block generic development.

The relevant intellectual-property categories are:

IP category	Relevance to Vectical
Calcitriol composition patents	Historically important but generally aged or expired
Topical formulation patents	May cover specific ointment compositions or concentration ranges
Manufacturing patents	May cover dispersion, blending, deaeration, or filling processes
Packaging patents	May cover delivery systems, tubes, or metered dispensers
Method-of-use patents	May address psoriasis treatment or dosing limitations
Trade secrets	Likely relevant to impurity control, blending order, and scale-up

The FDA Orange Book identifies Vectical under NDA 021421. Public Orange Book analysis should focus on listed patents, active exclusivity, and whether any patent certifications remain relevant to an abbreviated new drug application.[4] Because Vectical is an older topical product, the main competitive question is usually whether a developer can obtain approval with a therapeutically equivalent generic ointment rather than whether a fundamental patent blocks entry.

What Orange Book status does Vectical have?

Vectical’s regulatory exclusivity is no longer the principal commercial barrier. FDA approval dates and Orange Book records establish the product’s reference-drug status, while current patent listings determine whether an ANDA applicant must submit a Paragraph IV certification or can proceed on a Paragraph III or Paragraph II basis.[4,5]

For business planning, the relevant findings are:

• The reference product is a prescription topical drug.
• New chemical entity exclusivity has expired.
• Any remaining barrier would arise from listed patent claims, regulatory requirements, development complexity, or commercial scale.
• A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence or an FDA-accepted alternative for the topical product.

When does Vectical lose exclusivity and face generic competition?

Vectical’s core regulatory exclusivity expired years after its 2009 approval. The product is therefore structurally exposed to generic competition, subject to current Orange Book listings and FDA approval requirements.

For a generic applicant, the principal route is an ANDA referencing the Vectical drug product. The applicant would need to establish:

• The same active ingredient, calcitriol
• The same strength, 3 mcg/g
• The same dosage form, ointment
• Pharmaceutical equivalence
• Appropriate inactive-ingredient justification
• Product quality and stability
• Bioequivalence under the applicable FDA framework
• Labeling consistent with the reference product, unless authorized otherwise

Topical products can require more development work than their apparent simplicity suggests. FDA may evaluate comparative clinical endpoint data, pharmacodynamic equivalence, in vitro release, or other product-specific evidence depending on the product guidance and regulatory pathway.[6]

What generic entry risks exist for Vectical?

The generic-entry risk is high at the active-ingredient level but moderate at the product-development level.

High-risk factors for the incumbent

Calcitriol is a known active ingredient. The product is a conventional topical dosage form, and the reference formulation uses widely available excipients. These factors lower the barrier to initial formulation screening.

Moderate-risk factors for generic developers

The principal technical risks include:

• Achieving uniform distribution of 3 mcg/g calcitriol
• Controlling particle size and agglomeration
• Demonstrating stability at commercial scale
• Matching rheology and spreadability
• Establishing equivalence for an anhydrous ointment
• Avoiding adsorption to manufacturing equipment
• Managing low-dose assay variability
• Selecting a container that limits oxygen and light exposure

A developer that changes the excipient system may improve consumer acceptability but increase regulatory burden. A near-copy using mineral oil, petrolatum, polysorbate 80, and alpha-tocopherol may shorten development time but create limited commercial differentiation.

Which excipient platforms offer the strongest commercial opportunity?

Low-grease ointments

The most direct opportunity is a hydrocarbon-reduced ointment using a structured emollient system. Candidate excipients include hydrogenated polyisobutene, polydecene, dimethicone, isopropyl myristate, medium-chain triglycerides, and selected esters.

The design target is a product that retains the occlusive performance of petrolatum while reducing residue and transfer. The main risks are altered drug release, irritation, oxidation, and loss of physical stability.

Water-in-oil creams

A water-in-oil cream could improve spreadability and patient acceptance. It may also reduce the perception of greasiness. The tradeoffs include:

• Preservative selection
• Emulsion stability
• Microbial testing
• Water activity control
• Calcitriol partitioning between phases
• More complex scale-up

A cream platform may be commercially valuable for patients who discontinue ointment therapy because of cosmetic dissatisfaction. It would, however, require stronger evidence that the product is equivalent to the reference ointment.

Silicone-modified systems

Dimethicone and related silicone excipients can reduce tack and improve skin feel. Silicone-based systems may provide better barrier properties with less perceived greasiness. Their use requires careful evaluation of calcitriol solubility, drug release, tube compatibility, and skin deposition.

Anhydrous gel-ointments

An anhydrous gel can combine the stability advantages of an ointment with improved application characteristics. Structuring agents such as organogelators or silica derivatives may produce a more elegant product. The development challenge is maintaining uniform calcitriol distribution at very low concentration.

Metered-dose packaging

Packaging is an underdeveloped differentiation opportunity. A metered pump or dose-calibrated applicator could reduce under- or over-application. It could also help manage the product’s hypercalcemia-related exposure limits. The commercial benefit would be strongest for patients treating multiple plaques or recurring disease.

How does Vectical compare with other topical psoriasis products?

Product category	Typical strength	Formulation advantage	Commercial limitation
Calcitriol ointment	3 mcg/g	Vitamin D analog with low-concentration dosing	Greasy ointment, exposure restrictions
Calcipotriene cream or ointment	Product-specific	Broad generic availability	Calcium-related restrictions and irritation
Tacalcitol ointment	Product-specific	Vitamin D analog option in selected markets	Limited geographic availability
Topical corticosteroids	Multiple	Fast anti-inflammatory effect and broad familiarity	Skin atrophy and other chronic-use concerns
Tazarotene gel or cream	Multiple	Retinoid mechanism and nonsteroidal positioning	Irritation and tolerability issues
Nonsteroidal topical immunomodulators	Product-specific	Useful in sensitive areas for some indications	Different safety and labeling profiles

Vectical’s positioning is strongest where prescribers want a nonsteroidal vitamin D analog and where an ointment is acceptable. Its positioning is weaker against low-cost generic calcipotriene and against modern foam, spray, lotion, and cream vehicles that are easier to apply.

What FDA regulatory status affects commercial development?

The FDA product is approved for adults with mild-to-moderate plaque psoriasis. A follow-on developer must align the formulation, strength, dosage form, route, labeling, and performance with the reference product unless it pursues a different regulatory strategy.[1,6]

Key regulatory issues include:

• Comparative physicochemical characterization
• Assay and impurities
• Uniformity of delivered dose
• In vitro release testing
• Skin permeation and retention
• Irritation and sensitization
• Photostability
• Container-closure integrity
• Microbial quality
• Long-term and accelerated stability

A new cream, gel, foam, or lotion may not qualify as a straightforward equivalent ointment. It could require a distinct development and regulatory strategy, potentially including clinical efficacy and safety studies.

Which licensing and commercial opportunities are available?

The most attractive licensing models are:

1. ANDA-ready formulation licensing. A developer licenses a stable calcitriol ointment platform with manufacturing data and a proposed equivalence package.
2. Branded-generic commercialization. A company markets a cosmetically improved product while retaining the calcitriol 3 mcg/g positioning.
3. Geographic licensing. Rights can be divided across the United States, Europe, Canada, and emerging markets because product availability and vitamin D analog competition differ by jurisdiction.
4. Contract manufacturing partnerships. Semi-solid manufacturers with low-dose blending and aluminum-tube filling capabilities can reduce scale-up risk.
5. Device-enabled delivery. A package supplier or drug-delivery company can license a metered applicator or airless pump.
6. Combination-product development. A calcitriol product combined with another psoriasis active ingredient would create a new regulatory and IP profile but would also increase development complexity.

No major current licensing transaction is necessary to establish the commercial thesis. The opportunity exists primarily in formulation, manufacturing, packaging, and market access.

How strong is the Vectical patent estate?

Vectical’s patent estate is likely moderate to weak against a conventional generic ointment and stronger against narrowly claimed improved formulations or delivery systems.

Factor	Assessment
Active ingredient protection	Weak due to age of calcitriol technology
Reference-product exclusivity	Expired or commercially immaterial
Conventional ointment protection	Potentially narrow
Formulation know-how	Meaningful
Manufacturing barriers	Moderate
Packaging differentiation	Available for new entrants
Generic substitution risk	High
Branded reformulation opportunity	Moderate

The strongest defensible position for a new entrant would combine a differentiated excipient system with demonstrable patient-use benefits, robust stability, and proprietary packaging. A simple excipient substitution is unlikely to support durable pricing power without clinical or adherence evidence.

What revenue exposure and launch scenarios apply to Vectical?

Vectical’s revenue exposure is concentrated in psoriasis maintenance and nonsteroidal topical treatment. Generic entry would likely cause rapid price erosion if multiple ANDA products launch. The first approved generic could capture pharmacy substitution, while a branded reformulation could preserve value through improved tolerability or convenience.

Launch scenario	Likely commercial effect
First generic with near-copy ointment	Rapid price pressure and substitution
Several conventional generics	Commodity pricing and limited differentiation
Low-grease branded generic	Moderate premium if adherence improves
Metered-dose device	Higher development cost, possible premium positioning
Cream or foam reformulation	Larger patient appeal, greater regulatory burden
Combination product	Higher potential value, longer development timeline

The most defensible commercial strategy is a differentiated product that solves a specific barrier to use: greasiness, inaccurate dosing, packaging waste, or treatment convenience.

Key Takeaways

• Vectical is a 3 mcg/g calcitriol ointment for adult plaque psoriasis.
• Its core excipients are white petrolatum, mineral oil, polysorbate 80, and alpha-tocopherol.
• The main technical challenge is uniform, stable delivery of calcitriol at microgram strength.
• A conventional generic ointment faces high substitution risk and limited pricing power.
• Low-grease ointments, anhydrous gels, water-in-oil creams, silicone-modified systems, and metered packaging offer the clearest differentiation paths.
• The product’s regulatory exclusivity is no longer the main barrier to competition.
• Formulation know-how, stability control, packaging, and equivalence evidence are more important than active-ingredient patent protection.
• The strongest commercial opportunity is a patient-friendly branded generic or reformulation supported by measurable adherence and usability benefits.

FAQs About Vectical Excipient Strategy

Can Vectical be reformulated without changing calcitriol strength?

Yes. A reformulation can retain 3 mcg/g calcitriol while changing excipients, but the product may require a different regulatory pathway if the dosage form or performance differs materially from the reference ointment.

Is mineral oil essential to a generic Vectical formulation?

No. Mineral oil is a functional excipient, not the active ingredient. It can potentially be replaced, but the substitute must support stability, spreadability, drug uniformity, skin compatibility, and regulatory equivalence.

What packaging is best for calcitriol ointment?

An opaque aluminum tube or protective multilayer tube is generally preferable for limiting light and oxygen exposure. Airless pumps may improve dosing and usability but require container-closure and compatibility testing.

Can a calcitriol ointment be marketed as an over-the-counter psoriasis product?

Vectical is an FDA-approved prescription product. An over-the-counter switch would require a separate FDA regulatory determination, monograph alignment, labeling review, and evidence supporting nonprescription use.

Does a less-greasy calcitriol product have patent potential?

Potentially. Patentability would depend on novelty, nonobviousness, and claim scope covering the specific excipient system, performance characteristics, manufacturing process, or delivery device. Improved skin feel alone would not guarantee enforceable protection.

References

1. U.S. Food and Drug Administration. (2009). Vectical ointment prescribing information: Calcitriol ointment, 3 mcg/g.
2. National Library of Medicine. (n.d.). DailyMed: Vectical calcitriol ointment.
3. International Council for Harmonisation. (1996). ICH Q1B: Photostability testing of new drug substances and products.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Food and Drug Administration. (n.d.). Approved drug product and exclusivity information.
6. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs.